Tissue factor pathway inhibitor: An update of potential implications in the treatment of cardiovascular disorders

Expert Opinion on Investigational Drugs

Volumn 10, Issue 11, 2001, Pages 1925-1935

  Kaiser, B ^a   Hoppensteadt, D A ^a   Fareed, J ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Cardiovascular diseases; Clinical perspective; Disseminated intravascular coagulation; Heparins; Sepsis; Tissue factor; Tissue factor pathway inhibitor

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 7; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MEMBRANE PROTEIN; PLACEBO; RECOMBINANT NEMATODE ANTICOAGULANT PROTEIN C2; RECOMBINANT PROTEIN; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; BIOCHEMISTRY; BLEEDING; BLOOD CLOTTING; BLOOD VESSEL OCCLUSION; CARDIOVASCULAR DISEASE; CLINICAL STUDY; CLINICAL TRIAL; COMPLEX FORMATION; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISSEMINATED INTRAVASCULAR CLOTTING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDICATION; EXPERIMENT; HEART INFARCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; ISCHEMIC HEART DISEASE; META ANALYSIS; MORTALITY; NONHUMAN; PATHOGENESIS; PHARMACOLOGY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEPSIS; THROMBOSIS; TISSUE INJURY; UNSTABLE ANGINA PECTORIS;

ANIMALS; ANTICOAGULANTS; CARDIOVASCULAR DISEASES; DRUG INTERACTIONS; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; LIPOPROTEINS;

EID: 0035169891     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.11.1925     Document Type: Review

References (100)

1. A cell-based model of hemostasis
2. Tissue factor: An enzyme cofactor and a true receptor
3. Tissue factor signalling
4. Diverse functions of protease receptor tissue factor in inflammation and metastasis
5. Tissue factor as a therapeutic target
6. Regulation of coagulation by a multivalent Kunitz-type inhibitor
7. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor
8. Endogenous phosphorylation of the lipoprotein-associated coagulation inhibitor at serine-2
9. Recombinant full-length tissue factor pathway inhibitor fails to bind to the cell surface: Implications for catabolism in vitro and in vivo
10. The lipoprotein-associated coagulation inhibitor that inhibits the Factor VII-tissue factor complex also inhibits Factor Xa: Insights into its possible mechanism of action
11. Kinetics of Factor Xa inhibition by tissue factor pathway inhibitor
12. Kinetics of the inhibition of tissue factor-Factor VIIa by tissue factor pathway inhibitor
13. Inhibition of Factor VIIa/tissue factor-induced blood coagulation with particular emphasis upon a Factor Xa-dependent inhibitory mechanism
14. The extrinsic pathway inhibitor: A regulator of tissue factor-dependent blood coagulation
15. A computer modeling study of the interaction between tissue factor pathway inhibitor and blood coagulation Factor Xa
16. Regulation of extrinsic pathway Factor Xa formation by tissue factor pathway inhibitor
17. Recombinant TFPI and variants. Potential implications in the treatment of cardiovascular disorders
18. Tissue factor pathway inhibitor for cardiovascular disorders
19. Regulation of tissue factor pathway inhibitor expression in smooth muscle cells
20. Synthesis and expression of tissue factor pathway inhibitor by serum-stimulated fibroblasts, vascular smooth muscle cells and cardiac myocytes
21. Tissue factor pathway inhibitor inhibits aortic smooth muscle cell migration induced by tissue factor/Factor VIIa complex
22. Human recombinant tissue factor pathway inhibitor prevents the proliferation of cultured human neonatal aortic smooth muscle cells
23. Human recombinant tissue factor pathway inhibitor induces apoptosis in cultured human endothelial cells
24. Tissue factor pathway inhibitor inhibits endothelial cell proliferation via association with the very low density lipoprotein receptor
25. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model
26. Inhibition of tissue factor-mediated coagulation markedly attenuates stenosis after balloon-induced arterial injury in minipigs
27. Tissue factor pathway inhibitor attenuates procoagulant activity and upregulation of tissue factor at the site of balloon-induced arterial injury in pigs
28. Fibrin-rich and platelet-rich thrombus formation on neointima: Recombinant tissue factor pathway inhibitor prevents fibrin formation and neointimal development following repeated balloon injury of rabbit aorta
29. Topically applied tissue factor pathway inhibitor reduced intimal thickness of small arterial autografts in rabbits
30. Expression of exogenous tissue factor pathway inhibitor in vivo suppresses thrombus formation in injured rabbit carotid arteries
31. Adenovirus-mediated local expression of human tissue factor pathway inhibitor eliminates shear stress-induced recurrent thrombosis in the injured carotid artery of the rabbit
32. Thromboresistance of balloon-injured porcine carotid arteries after local gene transfer of human tissue factor pathway inhibitor
33. Combination of a brief irrigation with tissue factor pathway inhibitor (TFPI) and adenovirus-mediated local TFPI gene transfer additively reduces neointima formation in balloon-injured rabbit carotid arteries
34. Local gene transfer of tissue factor pathway inhibitor regulates intimal hyperplasia in atherosclerotic arteries
35. Role for tissue factor pathway in murine model of vascular remodeling
36. Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in mice
37. Tissue factor pathway inhibitor expression in atherosclerosis
38. Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity
39. Co-localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis
40. Expression, localization, and activity of tissue factor pathway inhibitor in normal and atherosclerotic human vessels
41. A new T-287C polymorphism in the 5′ regulatory region of the tissue factor pathway inhibitor gene. Association study of the T-287C and C-399T polymorphisms with coronary artery disease and plasma TFPI levels
42. Polymorphisms of the tissue factor pathway inhibitor (TFPI) gene in patients with acute coronary syndromes and in healthy subjects: Impact of the V264M substitution on plasma levels of TFPI
43. Polymorphisms of the tissue factor pathway inhibitor gene and the risk of restenosis after coronary angioplasty
44. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients
45. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina
46. Increased tissue factor pathway inhibitor in patients with acute myocardial infarction
47. Regulation of monocyte procoagulant activity in acute myocardial infarction: Role of tissue factor and tissue factor pathway inhibitor-1
48. Tissue factor/tissue factor pathway inhibitor system and long-term prognosis after acute myocardial infarction
49. Serum lipids and regulation of tissue factor-induced coagulation in middle-aged men
50. Plasma levels of free and total TFPI, relationship with cardiovascular risk factors and endothelial cell markers
51. Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: Evidence supporting a physiologic role for EPI as a natural anticoagulant
52. Immunodepletion of extrinsic pathway inhibitor sensitizes rabbits to endotoxin-induced intravascular coagulation and the generalized Shwartzman reaction
53. Tissue factor pathway inhibitor activity in severe sepsis
54. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation
55. Plasma tissue factor pathway inhibitor in disseminated intravascular coagulation: Comparison of its behavior with plasma tissue factor
56. Changes in plasma tissue factor pathway inhibitor levels during the clinical course of disseminated intravascular coagulation
57. Increased truncated form of plasma tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation
58. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia
59. Tissue factor pathway inhibitor does not influence inflammatory pathways during human endotoxemia
60. Tissue factor pathway inhibitor response does not correlate with tissue factor-induced disseminated intravascular coagulation and multiple organ dysfunction syndrome in trauma patients
61. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis
62. Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture
63. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease
64. An update on heparins at the beginning of the new millenium
65. Plasma tissue factor pathway inhibitor and tissue factor antigen levels after administration of heparin in patients with angina pectoris
66. Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration
67. The effect of heparin on tissue factor and tissue factor pathway inhibitor in patients with acute myocardial infarction
68. Antithrombotic therapy in acute coronary syndromes: Key notes from the ESSENCE and TIMI 11B
69. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: One-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Coronary Events
70. A critical review of clinical trials for low-molecular-weight heparin therapy in unstable coronary artery disease
71. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention
72. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery
73. Low molecular weight heparin in unstable coronary artery disease
74. Low-molecular-weight heparin therapy in percutaneous coronary intervention: The NICE 1 and NICE 4 trials. National Investigators Collaborating on Enoxaparin Investigators
75. Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: Evidence for a difference in antithrombotic action
76. Differential effects of low molecular weight heparin and unfractionated heparin on circulating levels of antithrombin and tissue factor pathway inhibitor (TFPI): A possible mechanism for difference in therapeutic efficacy
77. Partial depletion of tissue factor pathway inhibitor during subcutaneous administration of unfractionated heparin, but not with two low molecular weight heparins
78. Rebound activation of coagulation after treatment with unfractionated heparin and not with low molecular weight heparin is associated with partial depletion of tissue factor pathway inhibitor and antithrombin
79. Physiological function of tissue factor pathway inhibitor and interaction with heparins
80. Reactivation of unstable angina after the discontinuation of heparin
81. Heparin induces synthesis and secretion of tissue factor pathway inhibitor from endothelial cells in vitro
82. The effect of unfractionated vs. low molecular weight heparin on tissue factor pathway inhibitor levels in hospital inpatients
83. Effects of unfractionated and low molecular weight heparins on plasma levels of hemostatic factors in patients with acute coronary syndromes
84. Interaction of activated Factor VII and active site-inhibited Factor VII with tissue factor
85. Future possibilities in the regulation of the extrinsic pathway: rFVIIa and TFPI
86. Role of zymogen and activated Factor X as scaffolds for the inhibition of the blood coagulation Factor VIIa-tissue factor complex by recombinant nematode anticoagulant protein c2
87. Inherent flexibility in a potent inhibitor of blood coagulation, recombinant nematode anticoagulant protein c2
88. Dose-response study of recombinant Factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement
89. Ability of recombinant Factor VIIa to generate thrombin during inhibition of tissue factor in human subjects
90. Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation
91. Role of coagulation inhibitors in inflammation
92. Coagulation in severe sepsis: A central role for thrombomodulin and activated protein C
93. Recombinant human activated protein C: A system modulator of vascular function for treatment of severe sepsis
94. Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation
95. Efficacy and safety of recombinant human activated protein C for severe sepsis
96. Current drug treatment strategies for disseminated intravascular coagulation
97. Antithrombin III in animal models of sepsis and organ failure
98. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis
99. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: A controlled double-blind, randomized, multicenter study
100. Antithrombin III and sepsis